Latest Transformation News

xReality Group Limited reported a robust 36% revenue increase in FY25, driven by rapid expansion of its Operator XR platform and strategic balance sheet improvements. The company’s optimistic outlook for FY26 is underpinned by new contracts, AI investments, and international distributor expansion.

Elixir Energy has secured a specialized rig imported by Shell to drill the pivotal Lorelle-3 appraisal well in Queensland’s Taroom Trough, with operations set to begin in January 2026. This move aims to validate Elixir’s substantial gas resources adjacent to Shell’s acreage.

Mastermyne’s FY2025 AGM reveals resilience amid sector headwinds, operational disruptions, and legal proceedings, while positioning for growth with new leadership and contracts.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.

Saferoads Holdings has divested its Road Safety Rentals business for $10.8 million, repaid debt, and is now focusing on rebuilding its core product sales with new hires and product innovation.

Canadian Phosphate Limited has signed a non-binding Letter of Intent with Novaphos Inc. to explore advanced phosphate processing technology, aiming to produce high-grade phosphoric acid domestically for fertilizer and battery markets.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

Aspermont Limited has appointed John Stark and David Straface as interim directors, reinforcing its board with seasoned insiders during a pivotal growth phase focused on data and intelligence services for global resource sectors.

ReNerve Limited has raised $3.2 million through a two-tranche share placement to accelerate its sales and marketing efforts in the US and support upcoming product launches, including a new nerve conduit range.